Recent studies showed that lung cancer cells with the BIM deletion polymorphism and EGFR mutation are resistant to third-generation EGFR-TKIs, suggesting that the BIM deletion polymorphism has potential as a biomarker to predict the efficacy of third-generation EGFR-TKIs in patients [22]. Here, BCL2L11 is linked to lung cancer.